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Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular
events. This paper aims (i) to critically appraise evidence for elevated levels of triglyceride-rich lipoproteins (TRLs) and low levels of high-
density lipoprotein cholesterol (HDL-C) as cardiovascular risk factors, and (ii) to advise on therapeutic strategies for management. Current
evidence supports a causal association between elevated TRL and their remnants, low HDL-C, and cardiovascular risk. This interpretation is
based on mechanistic and genetic studies for TRL and remnants, together with the epidemiological data suggestive of the association for
circulating triglycerides and cardiovascular disease. For HDL, epidemiological, mechanistic, and clinical intervention data are consistent
with the view that low HDL-C contributes to elevated cardiovascular risk; genetic evidence is unclear however, potentially reﬂecting the
complexity of HDL metabolism. The Panel believes that therapeutic targeting of elevated triglycerides (≥1.7 mmol/L or 150 mg/dL), a
marker of TRL and their remnants, and/or low HDL-C (,1.0 mmol/L or 40 mg/dL) may provide further beneﬁt. The ﬁrst step should
be lifestyle interventions together with consideration of compliance with pharmacotherapy and secondary causes of dyslipidaemia. If inade-
quately corrected, adding niacin or a ﬁbrate, or intensifying LDL-C lowering therapy may be considered. Treatment decisions regarding statin
combination therapy should take into account relevant safety concerns, i.e. the risk of elevation of blood glucose, uric acid or liver enzymes
with niacin, and myopathy, increased serum creatinine and cholelithiasis with ﬁbrates. These recommendations will facilitate reduction in the
substantial cardiovascular risk that persists in patients with cardiometabolic abnormalities at LDL-C goal.
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Despite considerable improvements in medical care over the past
25 years, cardiovascular disease (CVD) remains a major public
health challenge. In Europe, CVD is responsible for nearly 50%
of all deaths and is the main cause of all disease burden,
1 with man-
agement costs estimated at E192 billion annually.
2 However, with
the increasing incidence of obesity, metabolic syndrome, and type
2 diabetes mellitus (T2DM),
3 this burden is projected to escalate
dramatically. At a time when Europe, like other developed
regions, is faced with the need to contain expenditure, urgent
action is needed to address this critical problem.
Current best treatment including lifestyle intervention and phar-
macotherapy aimed at lowering plasma concentrations of
low-density-lipoprotein cholesterol (LDL-C), reducing blood
pressure, and preventing thrombotic events fails to ‘normalize’
risk in people at high risk of CVD (i.e. SCORE . 5% for CVD
death
4 or 10-year Framingham risk score .20% for CVD
events
5). Individuals with acute coronary syndromes (ACS) are at
very high risk of recurrent events:  10% occur within the ﬁrst
6–12 months,
6,7 and  20–30% within 2 years.
8,9 As the risk of
recurrent events in statin-treated coronary heart disease (CHD)
patients increases incrementally with each additional feature of
the metabolic syndrome,
10 this implies that other CV risk factors
beyond LDL-C may deserve attention. These risk factors may be
modiﬁable, e.g. non-LDL-C dyslipidaemia, hypertension, and
abdominal obesity, or non-modiﬁable, e.g. age and gender. Thera-
peutic interventions targeted to the former group clearly hold
potential for reducing this high CV risk that persists even with
optimal treatment of LDL-C.
Post hoc analyses of prospective trials in ACS and stable CHD
patients reveal that elevated plasma levels of triglycerides and low
plasma concentrations of high-density lipoprotein cholesterol
(HDL-C) are intimately associated with this high risk, even at or
below recommended LDL-C goals.
11–14 Furthermore, in T2DM
patients,theUKPDSidentiﬁedHDL-Casthesecondmostimportant
coronary risk factor, after LDL-C.
15 Despite these data, guidelines
are inconsistent in their recommendations for proposed levels of
HDL-C or triglycerides either for initiation of additional therapies
or for targets for such treatments in patients at LDL-C goal.
4,5,16–19
The aim of this paper isto critically appraise the current evidence
relatingtotriglyceridesandHDL-CasCVriskfactorsormarkersand
toconsidertherapeuticstrategiesfortheirmanagement.Thefocusis
on individuals with cardiometabolic risk, characterized by the clus-
teringofcentralobesity,insulinresistance,dyslipidaemia,andhyper-
tension, which together increase the risk of CVD and T2DM.
18
The EAS Consensus Panel is well aware of uncertainties and
controversies regarding triglycerides and HDL-C levels, both as
risk markers or targets of therapy. Triglycerides are predominantly
carried in fasting conditions in very low-density lipoproteins
(VLDLs) and their remnants, and postprandially in chylomicrons
and their remnants. The generic term ‘triglyceride-rich lipoprotein
remnants’, therefore, relates to chylomicron and VLDL particles
which have undergone dynamic remodelling in the plasma after
secretion from the intestine (chylomicrons) or liver (VLDL)
(Figure 1). This remodelling results in a spectrum of particles
Figure 1 Upon entry into the circulation, chylomicrons (containing apo B-48) produced by the small intestine, and VLDL (containing apo
B-100) produced by the liver undergo LPL–mediated lipolysis mainly in peripheral tissues, notably adipose tissue and muscle. Intravascular
remodelling of TRL equally involves the actions of lipid transfer proteins (CETP, PLTP) and additional lipases (HL and EL) with the formation
of remnant particles. TRL remnants are typically enriched in cholesterol and apo E, but depleted in triglyceride; they are principally catabolized
in the liver upon uptake through the LRP and LDL receptor pathways. TRL remnants can contribute either directly to plaque formation follow-
ing penetration of the arterial wall at sites of enhanced endothelial permeability,
21 or potentially indirectly following liberation of lipolytic pro-
ducts (such as FFA and lysolecithin) which may activate pro-inﬂammatory signalling pathways in endothelial cells.
20,21 Abbreviations: apo,
apolipoprotein; CETP, cholesteryl ester transfer protein; EL, endothelial lipase; FFA, free fatty acids; HL, hepatic lipase; LDL, low-density lipo-
protein; LPL, lipoprotein lipase; LRP, lipoprotein receptor-related protein; PLTP, phospholipid transfer protein; TRL, triglyceride-rich lipopro-
tein; VLDL, very-low density lipoprotein.
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protein composition
20 and include intermediate-density lipopro-
tein (IDL) particles. No single biochemical trait allows the differen-
tiation of remnants from newly secreted chylomicrons, VLDL and
IDL.
21 Thus, plasma triglyceride levels correspond essentially to
the sum of the triglyceride content in nascent VLDL and their rem-
nants in the fasting state, together with that in chylomicrons and their
remnants in the postprandial state. Consequently, the Panel has used
the generic term ‘triglyceride-rich lipoprotein (TRL) remnants’ as a
surrogate for plasma levels of both newly secreted TRLs and their
remnants, the latter predominatingi nt h et y p i c a lp e r s o nw i t hc a r d i o -
metabolic risk.
21 As discussed below, increasing evidence suggests
that remodelled chylomicrons and VLDL are atherogenic, primarily
as a result of their progressive enrichment with cholesterol and
depletion of triglycerides in the plasma compartment. This process
also results in progressive reduction in their size. The term ‘TRL rem-
nants’ has been used to emphasize our focus on atherogenic lipopro-
teins themselves rather than their major lipids.
Similarly, the Panel understands that, despite epidemiologic data
and evidence from some animal models
22 implying a role for HDL
as anti-atherogenic and vasculoprotective lipoproteins, the meta-
bolic and functional pathways linking HDL-C levels and protection
from CVD are poorly deﬁned. The Panel also recognizes that HDL
represent a highly dynamic pool of heterogenous particles.
23 As
HDLparticlesvarygreatly intermsoflipidand protein composition,
it was decided to focus on HDL-C as the marker of CVD risk.
Lipid and lipoprotein metabolism
Cholesterol, in both free and esteriﬁed forms, and triglycerides are
the two main lipids in plasma. They are transported in lipoproteins,
pseudomicellar lipid–protein complexes, in which the main apoli-
poproteins, apo B-100/48, apo A-I, apo A-II, apo E, and the apo Cs,
are integral components. Apo B is a component of all atherogenic
lipoproteins (chylomicron remnants, VLDL and their remnants,
IDL, lipoprotein(a) [Lp(a)] and LDL), whereas apo A-I and
apo A-II are components of HDL. The apo B-containing lipopro-
teins and the apo A-I/A-II lipoprotein classes are closely inter-
related via several metabolic pathways (Figure 2).
23–25
In dyslipidaemic patients with cardiometabolic risk, increased free
fatty acid ﬂux may represent a signiﬁcant abnormality driving
increased hepatic assembly and secretion of VLDL, IDL, and/or
LDL particles, although other mechanisms are also implicated.
26,27
Low plasma levels of HDL-apo A-I are associated with its increased
Figure 2 Metabolic pathways for HDL and triglyceride-rich lipoprotein remnants highlight their close interrelationship. De novo production of
nascent HDL (discs) occurs in the liver and small intestine through the production of apo A-I (the major HDL protein) and lipidation (with
cholesterol and phospholipids) of this protein by the ATP-binding cassette transporter (ABCA1) in these organs. Upon secretion, lecithin:
cholesterol acyltransferase (LCAT) esteriﬁes cholesterol on these discs which mature into spherical particles (due to the formation of a hydro-
phobic core resulting from generation of cholesteryl esters by LCAT). HDL undergoes extensive interconversion through triglyceride lipolysis
(hepatic lipase, HL), phospholipid hydrolysis (endothelial lipase, EL), fusion (phospholipid transfer protein, PLTP), and lipid exchange among
the HDL subpopulations (cholesteryl ester transfer protein, CETP). CETP also mediates major lipid transfer and exchange between HDL and
triglyceride-rich lipoproteins (VLDL, chylomicrons) and their remnants [VLDL remnants ¼ intermediate-density lipoproteins (IDLs), chylomi-
cron remnants]. During this process, cholesteryl esters are transfered from HDL to VLDL and triglycrides move from VLDL to HDL.
24 Chy-
lomicrons also act as cholestery ester acceptors from LDL and HDL during the post-prandial phase.
25 A second route that contributes to the
plasma HDL pool involves hydrolysis of triglycerides in VLDL, IDL, and chylomicrons. In this process which is catalysed by lipoprotein lipase
(LPL), phospholipids, as well as several apolipoproteins (such as apo CI, CII, CIII, AV) are transferred to HDL. PLTP contributes signiﬁcantly
to this remodelling process.
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26 This is driven by both cholesteryl ester transfer
protein (CETP)-mediated heteroexchange of triglycerides from
apo B lipoproteins with cholesteryl ester from apo A-I lipoproteins,
and dissociation of apo A-I from triglyceride-enriched HDL with
clearance via the kidney.
26,28,29 Such metabolic perturbations are fre-
quently associated with insulin resistance, which may in turn inﬂu-
ence the activities of lipoprotein lipase (LPL), CETP and
potentially, hepatic lipase (HL), phospholipid transfer protein, and
endothelial lipase. Within this large dyslipidaemic group, however,
many patients do not exhibit insulin resistance but nonetheless
display a mixed dyslipidaemia characterized by elevated levels of
TRL and LDL. This lipid phenotype typically involves subnormal con-
centrations of HDL-C and increased cardiovascular risk.
30 Finally,
although there are close links, both pathophysiologic and genetic,
between the dyslipidaemia of insulin resistance and the phenotype
of familial combined hyperlipidaemia (FCHL),
31 some individuals
with elevated levels of TRL remnants do not have insulin resistance
or T2DM.
30,32,33 Such individuals are at increased risk for premature
CVD, although it is not clear if this risk is higher or lower than in
those with the dyslipidaemia of insulin resistance and/or T2DM.
Pharmacological correction of hypertriglyceridaemia in T2DM
does not usually normalize low apo A-I levels, which probably
reﬂects the complex mechanisms involved.
26,29 The complexity
of HDL metabolism is clearly relevant when strategies to raise
HDL-C are reviewed; indeed, HDL-C concentration is at most
an indirect marker of the anti-atherogenic activities that are
associated with this lipoprotein.
28
What is the experimental evidence
that triglyceride-rich lipoprotein
remnants and high-density
lipoprotein play a role
in the pathophysiology
of atherothrombosis?
The retention of cholesterol-rich lipoproteins within the suben-
dothelial matrix of the arterial wall is a key initiator of atherosclero-
sis.
34 Sites of endothelial dysfunction constitute preferential arterial
locations for lipoprotein penetration, accumulation, and plaque
formation.
34 Although LDL is considered the main atherogenic
cholesterol-rich particle, other apo B-containing lipoproteins (TRL,
their remnants, and Lp(a)) also contribute to intimal cholesterol
deposition, particularly as they contain a similar number of choles-
terol molecules per particle (  2000) as LDL.
21,35 In contrast,
HDLs were originally thought to readily enter the subendothelial
space and then return to the circulation,
36 although recent studies
highlight the need to reconsider this notion.
37
Experimental studies show that particle size is a key determinant.
While large chylomicrons and VLDL fail to penetrate the arterial
wall, their smaller remnants not only penetrate the arterial intima
but may be bound and retained by connective tissue matrix.
38,39
Accumulation of both chylomicron and VLDL remnants enriched
inapoEhasbeendemonstratedinhumanandrabbitatherosclerotic
plaques.
20,39–41 Such particles, also referred to as ‘b-VLDL’, can be
taken up directly by arterial macrophages with massive cholesterol
loadingandfoamcellformation.
42,43ElevatedlevelsofTRLremnants
havealsobeenlinkedtotheprogressionofcoronaryarterydisease
44
and the presence of echolucent carotid artery plaques.
45 Clearly,
TRL remnant cholesterol can contribute directly to plaque
formation and progression.
20
Triglyceride-richlipoproteinremnantsmayalsodriveatherogenesis
via indirect mechanisms, particularly those involving binding and lipo-
lysis at the arterywall.
20Such mechanisms provide a key link to accel-
erated atherogenesis in the postprandial phase. Acutelyelevated TRL
remnantsoccurringin this phaseare associated withimpaired vasodi-
lation,
46 upregulated pro-inﬂammatory cytokine production,
47 and
enhanced inﬂammatory response and monocyte activation.
48–51
All of these mechanisms may underlie endothelial dysfunction. More-
over, TRL remnants are of relevance to plaque disruption and sub-
sequent thrombus formation, key events in the onset of most
ACS.
52,53 Triglyceride-rich lipoprotein remnants stimulate the
secretion of tissue factor from endothelial cells and monocytes,
54
and promote thrombin generation at levels similar to those caused
by activated platelets.
55 Elevated triglycerides are linked with raised
concentrations of ﬁbrinogen and coagulation factors VII and XII, and
withimpairedﬁbrinolysisasdeterminedbyenhancedgeneexpression
and concentrations of plasminogen activator inhibitor-1.
56,57
In contrast to TRL remnants, HDLs display a wide spectrum of
biological activities (Box 1), of which cellular cholesterol efﬂux
activity, and anti-inﬂammatory and anti-oxidative actions are
key.
23,28 HDLs also contribute to pancreatic beta-cell func-
tion.
58–60 The functionality of HDL is potentially highly vasculo-
protective. HDLs maintain endothelial vasoreactivity, attenuate
oxidative stress, inhibit endothelial cell apoptosis, contribute to
the repair of damaged endothelium,
61,62 inhibit monocyte acti-
vation,
63 and reduce the expression of adhesion molecules and
cytokines.
28 Apo A–I may also immunoregulate lymphocytes and
mononuclear cells.
63,64 All of these actions may potentially attenu-
ate component steps of atherosclerotic plaque formation.
23,28,65
Box 1 HDL functionality: relevance
to athero/vasculo-protection
† Cellular cholesterol efﬂux and cholesterol homeostasis
† Regulation of glucose metabolism
† Anti-inﬂammatory activity
† Anti-oxidative activity
† Anti-apoptotic activity
† Endothelial repair
† Vasodilatory activity
† Anti-thrombotic activity
† Anti-protease activity
† Anti-infectious activity
To what degree can HDL counteract the prothrombogenic activity
of TRL remnants, particularly since insulin-resistant states associate
with thrombotic risk clustering?
57 HDL and apo A-I protect eryth-
rocytes against the generation of procoagulant activity
66 and
augment the anticoagulant activity of protein S. The latter enhances
the function of activated protein C, a critical factor in regulating
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and VIIIa.
67 HDL also affect platelet aggregation, inhibiting
thrombin-induced binding of ﬁbrinogen to platelets.
68 Finally, in
T2DM, in which HDL anti–atherogenic function is defective,
28
infusion of reconstituted (r)HDL increases the anti-inﬂammatory
and in vitro cholesterol efﬂux potential of HDL
69 and reduces plate-
let hyperreactivity by lowering the cholesterol content of platelet
membranes.
70 Considered together, these data suggest a unifying
hypothesis for the anti-atherothrombogenic actions of HDL and
point to a crucial role in cellular cholesterol homeostasis. Signiﬁ-
cantly, HDL-mediated cholesterol efﬂux activity from macrophages
was recently shown to be relevant both to carotid-intima thickness
and coronary artery disease.
71
A critical question is whether HDL impact long-term CV risk via
these effects on the atherosclerotic process. The data from animal
models have shown that overexpression of the human apo A-I
gene increases HDL-C levels, protecting against diet-induced ather-
osclerosis.
72 In addition, infusion of HDL or apo A–IMilano/phospho-
lipid complexes reduced aortic lipid deposition and induced
regression of atherosclerosis in rabbits.
73,74 In humans, infusion of
synthetic rHDL restored endothelial function in hypercholesterolae-
mic patients.
75 Infusion of recombinant apo A–IMilano/phospholipid
complexes reduced coronary atherosclerosis in ACS patients,
although there was no dose-dependent effect.
76 More recently,
rHDL infusion reduced atheroma volume in subjects with premature
coronary
77 or peripheral atherosclerosis.
78 Observational data from
four intravascular ultrasound trials (two with statins) showed that
lowering plasma apo B lipoprotein concentrations together with
simultaneous minor elevation of HDL-C levels achieved plaque
regression and stabilization.
79 All of these ﬁndings urgently require
conﬁrmation in larger randomized studies.
Thus, in summary, the data indicate that TRL remnants and HDL
are relevant throughout all stages of atherothrombosis, especially
within the context of the insulin resistance syndrome.
57
Prevalence of elevated
triglyceride-rich lipoprotein
remnants and low high-density
lipoprotein cholesterol
First, it is important to ascertain the prevalence of atherogenic
dyslipidaemia, i.e. the combination of elevated TRL remnants and/
or low HDL-C.
80 Among the general population plasma concen-
trationsoftotalcholesterol,LDL-CandHDL-Carenormallydistrib-
uted. In contrast, the distributions of triglycerides, remnant
cholesterol, apo B, and non-HDL-C (i.e. total cholesterol2HDL-C)
tendtobeskewedwithatailtowardthehighestlevels.IntheCopen-
hagen General PopulationStudy, low HDL-C levels werefrequently
associated with elevated levels of cholesterol and TRL remnants
(Figure 3). Approximately 45% of men and 30% of women in the
study had triglycerides ≥1.7 mmol/L (150 mg/dL) with or without
HDL-C , 1.0 mmol/L (40 mg/dL) (BG Nordestgaard, unpublished
results). HDL-C levels are lower in Turkish populations, largely
due to genetic predisposition.
81,82 The Turkish Heart Study
reported that  50% of men and  25% of women had HDL-C
levels ≤0.9 mmol/L(35 mg/dL).
82Asinothercountries,atherogenic
dyslipidaemia is on the rise, due to the increasing prevalence of the
metabolicsyndrome.IntheTurkishAdultsRiskFactorStudy,  40%
of men and 35% of women had triglycerides .1.7 mmol/L with or
without low HDL-C (≤0.9 mmol/L or 35 mg/dL).
83
Atherogenic dyslipidaemia is more prevalent in individuals at
high risk of CVD. In the Swedish National diabetes register includ-
ing .75000 T2DM subjects, 37–38% had untreated hypertrigly-
ceridaemia (.1.7 and ≤4.0 mmol/L, i.e. .150 and ≤354 mg/dL)
with or without low HDL-C.
84 More than one-third of the
CHD patients in EUROASPIRE III had elevated triglycerides
(≥1.7 mmol/L or 150 mg/dL) and/or low HDL-C;  50% of
patients from Turkey had low HDL-C.
85 In the PROCAM study,
Figure 3 Lipoprotein cholesterol as a function of increasing levels of non-fasting triglycerides in the general population. Based on non-fasting
samples from 36 160 men and women from the Copenhagen General Population Study collected over the period 2003–2007; 9% of men and
6% of women were on statins, mainly 40 mg/day simvastatin. Remnant cholesterol is calculated from a non-fasting lipid proﬁle as total choles-
terol minus HDL cholesterol minus LDL cholesterol; under these conditions, remnant cholesterol represents the total cholesterol transported
in IDL, VLDL, and chylomicron remnants. Variable levels of chylomicrons are present in non-fasting samples and usually will only contribute
minimally to the calculated remnant cholesterol. Nordestgaard BG 2010, unpublished results.
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ated triglycerides (≥2.28 mmol/L or 200 mg/dL) and/or low
HDL-C (,1.05 mmol/L or 40 mg/dL) vs. matched controls; CV
risk associated with this dyslipidaemic proﬁle was higher also at
low LDL-C levels.
86 Together, these observational data highlight
an unmet clinical need for treatment beyond LDL-C lowering in
patients at high risk of CVD with atherogenic dyslipidaemia.
What is the evidence that
triglyceride-rich lipoprotein
remnants and high-density
lipoprotein cholesterol contribute
to cardiovascular risk?
The data from epidemiological and genetic studies are relevant to
this question.
Epidemiology
General populations
Large observational studies clearly show that both elevated triglycerides
(either fasting or non-fasting)
87–90 and reduced plasma levels of
HDL-C
91–93 are associated with increased CV risk. Scepticism of
the role of elevated levels of TRL remnants in atherosclerosis and
CVDhaspersisteddespitetheobservationthatpatientswithdysbetalipo-
proteinaemia (remnant hyperlipidaemia) with accumulation of apo E and
cholesterol-richremnantstypicallydisplayprematureatherosclerosisand
high CVD risk.
94 Some suggested that individuals with lifelong, extremely
high triglycerides (25–300 mmol/L or 2200–26550 mg/dL) and familial
chylomicronaemia(e.g.duetoLPLdeﬁciency)didnotpresentwithaccel-
erated atherosclerosis.
94 Others observed the opposite,
95 consistent
with experimental data in animal models.
96,97 However, the rarity of
this disease prevents ﬁrm conclusions to be made.
The Emerging Risk Factors Collaboration (ERFC)
93 provides the
most robust evidence for the association of HDL-C with CV risk
(Figure 4). This analysis of 68 studies in 302430 participants
withoutpriorhistoryofCVDusedindividualparticipant data,allow-
ing for harmonization and consistent adjustment of confounding
factors, hitherto unfeasible. HDL-C was strongly associated with
coronary risk even after adjustment for non-HDL-C and loge trigly-
cerides and non-lipid risk factors. Each unit of standard deviation
(SD) increase in HDL-C concentration (0.38 mmol/L or 15 mg/dL)
was associated with 22% reduction in CHD risk. Importantly, this
protective effect was equal across the range of triglyceride levels.
However, it is acknowledged that the data are not clear for
HDL-C levels ,0.5 or .2.2–2.5 mmol/L (,19 mg/dL or .85–
100 mg/dL). Non-HDL-C and apo B each had very similar associ-
ationswithCHD.BothHDL-Candnon-HDL-Cwerealsomodestly
associated with ischaemic stroke (Figure 4), but not haemorrhagic
stroke.
While coronary risk was increased by 37% (95% CI 31–42%)
per SD increase in loge triglycerides, this association was weakened
after adjustment for HDL-C and abrogated after correction for
non-HDL-C. Additionally, triglycerides were not associated with
stroke risk after adjustment for other lipid factors.
93 These data
are compatible with the view that it is the number of TRL and
remnant particles that cause CVD. Thus, the risk associated with
elevated triglycerides can be explained by this lipid acting as a
marker for increased numbers of TRL, which in turn are closely
associated with the combination of higher levels of non-HDL-C
and low levels of HDL-C. In the Copenhagen City Heart Study,
increased risk for MI, ischaemic stroke, and mortality was evident
at markedly elevated triglycerides (.5.0 mmol/L or .450 mg/dL),
although these data were not adjusted for non-HDL-C
(Figure 5).
89,90 Thus, low HDL-C and elevated non-HDL-C and
triglycerides appear to be relevant to CV risk beyond LDL-C.
Clinical trial populations
Epidemiological evidence for low HDL-C as a major, independent
CV risk factor is strengthened when considering clinical trial data
in high-risk statin-treated patients (Table 1).
12,98–100 In the TNT
study,lowon-treatmentHDL-Cconcentrationwasasigniﬁcantpre-
dictorforcoronaryeventsatlowLDL-C(,1.8 mmol/Lor70 mg/dL),
even after adjustment for CV risk factors, including on-treatment
LDL-C and triglycerides and baseline HDL-C.
12 A meta-regression
analysis questioned the relevance of HDL-C to CV risk, although
methodological issues may limit its validity
101 [the analysis included
299 310 participants at risk of CV events in 108 studies of any lipid-
modifying agent (either as monotherapy or in combination) or diet/
surgery with a minimum of 6 months follow-up. There were no
signiﬁcant associations between the treatment-induced change in
HDL-C and risk ratios for CHD events, CHD death, or total mor-
tality after adjustment for changes in LDL-C. However, there are a
numberofimportantmethodologicalissueswiththisanalysisinclud-
ing: (i) the use of aggregated data rather than individual subject data;
(ii) the method of analysis which describes an observational associ-
ation and therefore risks bias by confounding; (iii) the combination
of treatments and diets with important differences in pharmacology
or mechanism of action; and (iv) failure to take account of the effect
of baseline lipid proﬁle which is known to inﬂuence the extent of
HDL-C-raising]. Recently, a meta-analysis of 170 000 subjects in 26
statin trials (24 332 CVD events) showed that irrespective of the
achieved LDL-C level or the intensity of statin therapy, CV risk
wasalwayslowerathigherlevelsofachievedHDL-C,withnoattenu-
ation of this relationship at low LDL-C levels. The lowest risk was
observed in those with both a low LDL-C and a high HDL-C.
100
This largely refutes suggestions that HDL-C concentration may be
less predictive at very low LDL-C levels as in the JUPITER trial
(393 CV events).
102
While the 4S trial showed no association between on-treatment
levels and changes from baseline levels for triglycerides and
reduction in CV risk,
103 data from more recent trials are indicative
of association.
11,104,105 In the PROVE IT-TIMI 22 trial, on-treatment
triglycerides ,1.7 mmol/L (,150 mg/dL) were independently
associated with a lower risk of recurrent coronary events in
ACS patients at LDL-C goal (,1.8 mmol/L or 70 mg/dL).
11
Further, pooled analysis of the TNT and IDEAL trials showed a
trend for decreased CV event risk with lowering of triglycerides
(P , 0.001), although this was attenuated by adjustment for
HDL-C and the ratio of apo B/apo A–I.
104
In T2DM patients, the FIELD and ACCORD Lipid studies showed
that marked atherogenic dyslipidaemia (triglycerides ≥2.3 mmol/L
or 204 mg/dL and low HDL-C levels (≤0.88 mmol/L or 34 mg/dL
M.J. Chapman et al. 1350inACCORDLipid)wasassociatedwithincreasedCVeventrates(by
 30–70%vs.thosewithoutthisproﬁle).
106,107AnalysesfromFIELD
show that the hazard ratios for HDL-C, apo A–I, apo B, and
non-HDL-C were comparable for the prediction of CV risk
whereas that for serum triglycerides was attenuated by adjustment
for HDL-C (P ¼ 0.07),
108 concordant with the ERFC analysis.
Taken together, these observational and clinical trial data
support the view that (i) a low HDL-C concentration is associated
with CVD independent of LDL-C (or non-HDL-C) levels, and (ii)
that elevated triglycerides are moderately associated with CVD,
potentially largely through the number of TRL remnants. Thus,
while LDL-C lowering remains the ﬁrst priority, therapeutic
targeting of low HDL-C and elevated TRL remnants may offer
the possibility of incremental reduction in CV risk in high-risk
populations.
Genetic studies of triglyceride and
high-density lipoprotein metabolism
In contrast, genetic studies do not provide clear insights into CV
risk associated with changes in plasma triglycerides and HDL-C
levels. This is not unexpected as predictions based on epidemiolo-
gical studies may be inappropriate tools to assess complex biologi-
cal pathways, especially for HDL metabolism. Monogenic disorders
of triglyceride metabolism (involving functional mutations in the
LPL, APOCIII, APOAV, LMF1, and GPIHBP1 genes) and HDL metab-
olism (involving the APOAI, LCAT, ABCA1, LIPC, LIPG, CETP, and
SCARB1 genes) have so far failed to provide answers,
109 probably
due to the rarity of these disorders. On the other hand, there is
unequivocal evidence for markedly accelerated atherosclerosis
and CVD in dysbetalipoproteinaemia, a familial dyslipidaemia in
which the critical defect is homozygosity for the receptor
binding-defective form of apo E, i.e. apo E2/E2,
94 resulting in
Figure 4 Hazard ratios for coronary heart disease and ischaemic stroke across quantiles of usual concentrations of triglycerides, HDL, and
non-HDL cholesterol levels. Reproduced with permission from the Emerging Risk Factors Collaboration.
93 Copyright& (2009) American
Medical Association. All rights reserved.
TRL and HDL-C in patients at high risk of CVD 1351markedly elevated plasma levels of TRL remnants enriched in
cholesterol and apo E.
Studies of frequent genetic coding variants and single-nucleotide
polymorphisms (SNPs) in non-coding DNA (with no known direct
functional signiﬁcance), such as in the LPL gene, showan association
between the combination of elevated triglycerides and low HDL-C
and an increase in CV risk.
110–114 In the initial genome-wide associ-
ationstudies(GWAS),variationatHDLlociwasnotassociatedwith
...............................................................................................................................................................................
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Table 1 Overview of epidemiological evidence in community and clinical intervention populations supporting the
association of low high-density lipoprotein cholesterol and/or elevated triglycerides with cardiovascular disease
Data source Population Key ﬁndings
HDL-C
ERFC
93 General population, no prior CVD HDL-C was independently predictive of coronary events and ischaemic stroke, even
after adjustment for lipid and non-lipid risk factors
SPARCL
98 Patients with previous
cerebrovascular disease
Greater decrease in recurrent stroke risk with on-treatment HDL-C levels above vs.
below the median (1.2 mmol/L), independent of change in LDL-C
CTT
99,100 Primary and secondary prevention,
on statin
Irrespective of achieved LDL-C levels or statin intensity, CV risk was lower at higher
levels of achieved HDL-C. This was not attenuated at low LDL-C levels
TNT
12 CHD, on potent statin therapy Predictive power of low on-treatment HDL-C concentrations remained even at low
LDL-C (,1.8 mmol/L)
MIRACL
13 ACS, on statin HDL-C but not LDL-C was an independent predictor of short-term prognosis after ACS
Triglycerides
ERFC
93 General population, no prior CVD The association of triglycerides and CV outcomes disappeared after adjustment for
HDL-C and non-HDL-C
PROVE-IT TIMI 22
11 ACS, on potent statin therapy On treatment triglycerides ,1.7 mmol/L were independently associated with a lower
risk of recurrent coronary events in ACS patients at LDL-C goal (,1.8 mmol/L)
Pooled analysis of
IDEAL and
TNT
104,105
Secondaryprevention(CHD,ACS)
on potent statin therapy
Decrease in CV events with lowering of triglycerides (P , 0.001 for trend); association
attenuated by adjustment for HDL-C and apo B/apo A-I
ACS, acute coronary syndromes; apo, apolipoprotein; CV, cardiovascular; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CTT,
Cholesterol Treatment Trialists’ Collaboration; ERFC, Emerging Risk Factors Collaboration; IDEAL, Incremental Decrease in Clinical Endpoints Through Aggressive Lipid
Lowering; MIRACL, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; PROVE-IT TIMI 22, Pravastatin or Atorvastatin Evaluation and Infection Therapy–
Thrombolysis in Myocardial Infarction 22; TNT, Treating to New Targets (study).
Figure 5 Relationship of non-fasting triglycerides (up to and .5 mmol/L or 440 mg/dL) and risk of myocardial infarction, ischaemic stroke,
and total mortality. Results are shown as age-adjusted hazard ratios from the Copenhagen City Heart Study with 26–31 years of follow-up.
Reproduced with modiﬁcation from Nordestgaard et al.
89 and Freiberg et al.
90 Copyright& (2007, 2008) American Medical Association. All
rights reserved.
M.J. Chapman et al. 1352CVD risk; however, a recent meta-analysis identiﬁed four novel loci
associated with CHD that were related to HDL-C or triglycerides
(but not LDL-C), suggesting that pathways speciﬁcally relating to
HDL or triglyceride metabolism may also modulate coronary
risk.
115 Collaborative analysis of a speciﬁc APOA5 variant
(21131T.C) that regulates triglycerides showed an association
with coronary risk. The odds ratio for CHD (1.18, 95% CI 1.11–
1.26) per C allele was also concordant with the hazard ratio (1.10,
95% CI 1.08–1.12) per 16% higher triglyceride concentrations in
prospective studies, suggesting a causal association between
triglyceride-mediated pathways (speciﬁcally high levels of remnant
lipoproteins and low HDL-C) and CHD.
116
Data for gene variants associated with isolated changes in plasma
HDL-C levels are more conﬂicting. For example, increased plasma
levels of HDL-C were correlated with increased CV risk in individ-
uals with SNPs in the LIPC gene associated with reduced HL
activity.
117–119 In contrast, genetic variants in ABCA1 associated
with substantial reductions in HDL-C levels (with no changes in
other lipids) were not associated with increased CV risk.
120 On
the other hand, three common CETP genotypes (TaqIB, I405V,
and 2629C.A) associated with lower CETP activity and higher
HDL-C levels were inversely associated with coronary risk.
114 In
GWAS of genes known to impact HDL metabolism, the effects
that such variants exert on HDL-C levels account for ,5% and
frequently ,2% of variability.
121,122 These data imply that in the
general population, HDL-C concentration represents the integral
sum of many gene effects on HDL metabolism. The current litera-
ture on the human genetics of HDL and TRL and their remnants
highlights the need for clariﬁcation of the interaction between
genes and different metabolic pathways, particularly for HDL.
What is the clinical evidence that
modulation of triglyceride-rich
lipoprotein, their remnants, and
high-densitylipoproteincholesterol
impacts atherosclerosis and
cardiovascular disease?
Lifestyle approaches
Lifestyle interventions inﬂuence the metabolism of HDL and TRL
remnants (Table 2).
123–140 Smoking increases TRL remnants and
decreases HDL-C levels,
141 secondary to insulin resistance and
hyperinsulinaemia;
142 these effects are rapidly reversed on quit-
ting.
123 Aerobic exercise causes long-lasting reduction in triglycer-
ides by up to 20% and increases in HDL-C by up to 10%, although
the same effects should not be assumed with progressive resistance
training (Table 2). In T2DM subjects, intensive lifestyle intervention
(weight loss, diet, and increased physical activity) had beneﬁcial
effectsonglycaemiccontrolandcardiometabolicriskfactors,includ-
ing HDL-C and triglycerides,
143–145 and, in the longer term was
associated with reduction in CVD risk.
146 Other trials showed
reduction in risk of progression to diabetes in people with impaired
glucose tolerance,
147,148 and improvement in other atherogenic
processes including inﬂammation with physical activity.
127
In CHD patients, lifestyle intervention trials have shown reduced
progressionofatherosclerosis,
149–151aswellasreductionintherisk
of CVevents.
152–154 Both the Diet and ReinfarctionTrial
153 and the
Lyon Diet Heart Study
154 showed substantial reduction in coronary
events (by at least 50%) with lifestyle intervention in MI survivors,
but require replication to conﬁrm these beneﬁts. However, while
ahealthylifestyleclearlyisimportantinreducingCVrisk,poorlong-
term adherence is a problem, and therefore many of these patients
require additional pharmacological intervention.
Clinical intervention studies
Statintherapyalone,inadditiontobeststandardsofcare,isunableto
completely normalize CV risk associated with atherogenic dyslipi-
daemia. Higher doses may partially correct residual dyslipidaemia,
but can also increase the risk of side effects, especially myopathy.
Addition of ezetimibe or bile acid resins to statin therapy has little
effectontriglyceridesandHDL-Clevels;resinsmayevenraisetrigly-
cerides. Evidence is supportive of therapeutic approaches aimed at
concomitantly lowering TRL and raising HDL-C to reduce CV
risk.
155 Of these options, both niacin and ﬁbrates inﬂuence levels
ofmultiplelipidsandlipoproteins(Box2
35,156,157)andthereforeclini-
callybeneﬁcialeffectsobservedcannotbeascribedsolelytochanges
in any single lipoprotein fraction. Pathways implicated in the lipid
effects of niacin, ﬁbrates, and omega-3 fatty acids are summarized
in Table 3.
158–170
Box 2 Lipid effects of niacin, ﬁbrates
and omega-3 fatty acids
△ LDL-C △ HDL-C △ TG △ Lp(a)
Niacin
(ER, 2 g/day)
  20%   up to
30%
a
  up to
35%
  up to
30–40%
† Effects are
dose-dependent
  large
LDL
  large
HDL
Fibrates Variable
b   by
5–20%
c
  by
25–50%
No
effect † Response
dependent on
baseline levels
b
  large
LDL
Omega-3 fatty
acids
 /no
change
 /no
change
  by
20–50%
No
effect
a Consistent HDL-C raising by up to 25% has been observed in patients with T2DM.
bEffects depend on the individual ﬁbrate, baseline lipid proﬁle, and metabolic nature
of dyslipidaemia.
cAlthough increases in HDL-C with ﬁbratesmay be up to 20% in short-term studies,
in long-term outcome studies in patients with T2DM the response to fenoﬁbrate
was much less (,5% at study close out), suggesting that ﬁbrate treatment may be
ineffective for raising HDL-C in this patient group.
Niacin
Niacin at therapeutic doses has a broad spectrum of effects on lipid
and lipoprotein metabolism, including raising of HDL-C (Box 2).
156
While various pathways are implicated,
158–161 its mechanism of
action is incompletely elucidated (Table 3). Niacin may also
promote beneﬁcial vasoprotective and anti-inﬂammatory effects
independent of its lipid-modifying activity.
171–173
TRL and HDL-C in patients at high risk of CVD 1353Imaging trials clearly document attenuated progression of ather-
osclerosis and intima-media thickening by niacin (Supplementary
material online, Table S1).
174–182 The only major outcome study
to date, the Coronary Drug Project, showed that niacin
(immediate-release 3 g/day) was associated with a 26% reduction
in non-fatal MI (P , 0.005) at 6–7 years, and 11% reduction in all-
cause mortality (P ¼ 0.0004) at 15 years ( 9 years after the end of
treatment).
183,184 These clinical beneﬁts were similar in patients
with or without hyperglycaemia, diabetes, or metabolic
syndrome.
185,186 A recent meta-analysis of niacin studies has
conﬁrmed these ﬁndings.
187
Niacinmayincreaseinsulinresistancetoaminordegree,although
this may be potentially counterbalanced by recently documented
protective effects of HDL on pancreatic beta cells.
58,59 In the
ADMIT and ADVENT studies in diabetic patients, potentially dele-
teriouseffectsonglycaemiawereeffectivelycounteractedbyadjust-
inganti-diabeticmedication.
188,189However,theriskofnewincident
diabetesinducedbyniacinininsulin-resistantorpre-diabeticindivid-
uals remains indeterminate.
In patients with atherogenic dyslipidaemia, the combination of
niacin plus statin improved the lipid-modifying efﬁcacy of statin
alone and was generally well-tolerated.
190–192 Combination of
niacin with laropiprant, an inhibitor of the prostaglandin D2 recep-
tor,
193signiﬁcantlyreducedbutdidnotabolishﬂushing,themaintol-
erability issue. Among patients with T2DM, transient impairment of
glucose control was reported (median increase in HbA1C 0.3% over
12 weeks),
194,195 consistent with known effects with niacin.
188,189
Emerging evidence suggests that statin plus niacin can reduce pro-
gression of atherosclerosis in high-risk patients, including those
with low LDL-C, as in the Oxford Niaspan trial
182 (Supplementary
material online, Table S1). There are limited data concerning the
risk of myopathy with niacin-statin combination therapy. Deﬁnitive
evidence regarding the longer-term risks of incident diabetes, myo-
toxicity, and hepatoxicity are awaited from the HPS2–THRIVE and
AIM-HIGH trials (projected enrolment 25000 and 3300, respect-
ively). Data from AIM-HIGH are expected in early 2013.
Insummary(Box3),evidencefortheanti-atheroscleroticactionof
niacinisrobust.
156Ameta-analysisalsosuggeststhataddingniacinto
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Table 2 Effects of lifestyle interventions on plasma concentrations of HDL cholesterol and triglycerides
Intervention △HDL-C Mechanism △triglycerides Mechanism
Smoking cessation
123   5–10%   LCAT and cholesterol
efﬂux;
 CETP
No signiﬁcant change
reported
–
Weight loss
124   during active weight loss   LCAT, LPL,
cholesterol efﬂux
  by 0.015 mmol/L
per kg weight loss
  VLDL clearance
  after weight stabilization
by 0.009 mmol/L per kg
weight lost
  catabolism of
HDL, apo A-I
  hepatic VLDL secretion
Exercise
125–131
Aerobic   5–10% (moderate to
high intensity)
  pre-b HDL, cholesterol
efﬂux, LPL
  10–20% (moderate
to high intensity)
  hepatic VLDL-TG
secretion;
  in HDL size    30% in VLDL-TG Beneﬁcial adaptations in
muscle ﬁbre area,
capillary density,
glycogen synthase, and
GLTU4 protein
expression in T2DM or
impaired glucose
tolerance
Resistance No signiﬁcant
change reported
Improved HDL functionality   5%
Alcohol
132–134   5–10% (1–3 drinks/day)   ABCA1, apo A-I Variable response,
   in obese subjects
  synthesis of VLDL–TG
with excess intake
  CETP    with excess intake
Dietary factors
135–140
n-3-PUFAs,
n-6-PUFAs, MUFAs
0t o  5% Improves ratio of LDL-C/
HDL-C
  10–15%   TG-rich lipoprotein
clearance via pathways
mediated by apo CIII and
apo E
Improves HDL
anti-inﬂammatory activity
  VLDL apo B secretion
Omni-Heart   by ,5%   56% (increased protein)
  33% (increased USFA)
ABCA1, ATP-binding cassette transporter; apo, apolipoprotein; CETP, cholesteryl ester transfer protein; GLUT4, glucose transporter type 4; HDL, high-density lipoprotein;
LCAT, lecithin:cholesterol acyltransferase; LDL, low-density lipoprotein; LPL, lipoprotein lipase; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; TG,
triglycerides; T2DM, type 2 diabetes mellitus; USFA, unsaturated fatty acids; VLDL, very low-density lipoprotein.
M.J. Chapman et al. 1354a statin may provide superior reduction in CV risk beyond that
achieved with statin alone.
187 The results of HPS2-THRIVE and
AIM–HIGHwill helpdiscern whetherniacin–statin therapy iseffec-
tive across a wide spectrum of dyslipidaemic patients, or only in
those with high triglycerides/low HDL-C dyslipidaemia.
Box 3 Impact of niacin on
atherosclerosis and clinical outcomes
† Anti-atherosclerotic effects of niacin in combination with a
statin have been extensively documented in plaque
imaging studies in coronary and carotid arteries
(see Supplementary material online, Table S1)
† Meta-analysis of niacin trials, several of which involved
small patient numbers, is indicative of clinical beneﬁt in
patients with cardiometabolic disease
187
† Ongoing trials (AIM-HIGH, HPS2-THRIVE) will evaluate
whether ER niacin on top of statin therapy can reduce
the CV risk that typically persists despite statin monother-
apy in patients with atherogenic dyslipidemia and cardio-
metabolic disease
† HPS2-THRIVE, given the broad range of patients, will
reveal whether niacin–statin therapy is effective across a
wide spectrum of dyslipidaemic patients or only in those
with high triglycerides/low HDL-C dyslipidaemia
Fibrates
Fibrates impact multiple pathways of lipid metabolism and may
equally exert pleiotropic effects via regulation of genes inﬂuencing
vascular inﬂammation and thrombogenesis. Their lipid-modifying
effects (Box 2) are mediated primarily via interaction with
peroxisome proliferator-activated receptor alpha (PPARa)
(Table 3).
156,162–166
Angiographic trials showed that ﬁbrate therapy may attenuate
atherosclerosis progression,
196–198 although the impact on the
progression of intima–media thickening has not been consist-
ent
199–201 (Supplementary material online, Table S2). Results
from individual monotherapy outcomes trials have been variable
and primarily indicate a reduction in nonfatal MI and revasculariza-
tion, with no effect on stroke or CV death,
202–207 subsequently
conﬁrmed by a meta-analysis.
208 Post hoc analyses of several of
these trials provided consistent evidence suggestive of clinical
beneﬁt in the subgroup of patients with elevated triglycerides
and low HDL-C (Table 4).
106,206,209,210 Indeed, a recent
meta-analysis conﬁrmed enhanced beneﬁt with ﬁbrates in patients
with atherogenic dyslipidaemia vs. those without.
211 On the basis
of such evidence, ﬁbrate treatment appears appropriate in this
subgroup (Box 4).
Box 4 Statin-ﬁbrate combination
therapy: current status
† Recent evidence from a meta-analysis suggests that ﬁbrate
therapy on a background of statin treatment provides clini-
cal beneﬁt in subgroups of patients with atherogenic dysli-
pidemia (Table 4)
† A large prospective trial to determine the long-term cardi-
ovascular effects of a statin–ﬁbrate combination in patients
with the high triglyceride and low HDL-C phenotype is
urgently needed
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Table 3 Mechanisms implicated in the lipid-modifying activity of niacin, ﬁbrates and omega-3 fatty acids
Drug Proposed mechanisms
Niacin
156,158–161,166 Not clear. the following have been implicated:
  TG synthesis and hepatic secretion of VLDL
Possibly, direct inhibition of DGAT-2
Partial inhibition of hormone sensitive TG lipase in adipose tissue
Up-regulation of apo A-I production
Possibly, delayed catabolism of larger HDL particles
Potential attenuation of CETP activity
Fibrate
156,162–166 Transcriptional regulation mediated via interaction with PPARa. Pathways involved include:
  catabolism of VLDL, IDL, and LDL apo B100 due to   LPL expression and activity
  production rate of apo CIII, thereby potentiating LPL activity (fenoﬁbrate)
  VLDL apo B or VLDL-TG turnover (bezaﬁbrate, gemﬁbrozil)
  production of apo A-II and lipoprotein AI:AII although no change in lipoprotein A-I with fenoﬁbrate
  HDL2a/HDL3a,linked to reduced CETP activity
Omega-3 fatty acids
138,157,167–170 Transcriptional regulation of SREBP-1c and PPARa
Inhibition of hormone-sensitive TG lipase and stimulation of LPL possibly through regulation of PPARd
  TG secretion and and lipogenesis
  mitochondrial and peroxisomal fatty acid oxidation
Inhibition of DGAT-2
  VLDL B secretion, speciﬁcally VLDL1
  conversion of VLDL to LDL
  catabolism of HDL apo A-I
apo, apolipoprotein; CETP, cholesteryl ester transfer protein; DGAT-2, diacylglycerol O-acyltransferase 2; IDL, intermediate-density lipoproteins; LPL, lipoprotein lipase; PPAR,
peroxisome proliferator-activated receptor; SREBP, sterol regulatory element binding proteins; TG, triglycerides; VLDL, very low-density lipoproteins.
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Table 4 Subgroup analyses of cardiovascular outcome studies with ﬁbrates
Trial Treatment
(mg/day)
Patient characteristics All patients Elevated triglycerides and low HDL-C subgroup
Primary endpoint Relative risk
reduction
Primary
endpoint
Lipid criteria
mmol/L
Relative risk
reduction
Fibrate monotherapy vs. placebo
WHO trial
202
(n ¼ 5331)
Cloﬁbrate 1600 Upper-third of cholesterol
values, without CHD
Non-fatal MI + CHD death 20% (P , 0.05) – – –
CDP
203
(n ¼ 3892)
Cloﬁbrate 1800
(n ¼ 1103)
CHD Nonfatal MI + CHD death 9% (P ¼ 0.12) – – –
HHS
204,209
(n ¼ 4081)
Gemﬁbrozil 1200 Non-HDL-C ≥200 mg/dL
without CHD
Fatal + non-fatal MI + cardiac death 34% (P , 0.02) As for all patients TG .2.3 +
HDL-C ,1.08
65% (P ¼ 0.01)
VA-HIT
205,210
(n ¼ 2531)
Gemﬁbrozil 1200 CHD + low HDL-C
(,40 mg/dL)
Non-fatal MI + CHD death 22% (P ¼ 0.006) As for all patients TG .2.03 +
HDL-C ≤1.03
28% (P , 0.05)
BIP
206
(n ¼ 3090)
Bezaﬁbrate 400 Previous MI or angina Fatal + non-fatal MI + sudden death 9.4% (P ¼ 0.26) As for all patients TG ≥2.26 +
HDL-C ,0.91
42% (P ¼ 0.02)
FIELD
106,207
(n ¼ 9795)
Fenoﬁbrate 200 Type 2 diabetes
(22% with CVD)
Non-fatal MI + CHD death 11% (P ¼ 0.16) Total CV events TG ≥2.30 +
low HDL-C
a
27% (P ¼ 0.005)
Statin-ﬁbrate vs. statin monotherapy
ACCORD Lipid
107
(n ¼ 5518)
Fenoﬁbrate 160
+ simvastatin
Type 2 diabetes
(37% with CVD)
CVD death, nonfatal MI + non-fatal
stroke
8% (P ¼ 0.32) As for all patients TG ≥2.30 +
HDL-C ≤0.88
31%; P-value not
reported
aIn FIELD, low HDL-C was deﬁned as ,1.03 mmol/L in men and ,1.29 mmol/L in women.
CHD, coronary heart disease; CV, cardiovascular; MI, myocardial infarction; WHO, World Health Organization.
ACCORD, Action to Control Cardiovascular Risk in Diabetes; BIP, Bezaﬁbrate Infarction Prevention study; CDP, Coronary Drug Project; FIELD, Fenoﬁbrate Intervention and Event Lowering in Diabetes study; HHS, Helsinki Heart Study;
VA-HIT, Veterans Affairs HDL Intervention Trial.
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6Combination of a statin with a ﬁbrate (primarily fenoﬁbrate) incre-
mentally decreased plasma triglycerides by 15–20% and raised
HDL-C by 5–20% vs. statin monotherapy.
212–215 Similar effects
were seen in FIELD and ACCORD Lipid, although the
placebo-corrected increments in HDL-C in the total study cohorts
were less than 3%.
107,207 In ACCORD Lipid, the only completed
outcome study of combination therapy, fenoﬁbrate–simvastatin had
noeffectontheprimaryoutcomevs.simvastatinaloneforallpatients.
Importantly, however, in the fenoﬁbrate–simvastatin group, there
wasa31%reductioninCVriskinthesubgroupwithbaselinetriglycer-
ides in the upper tertile (≥2.3 mmol/L or 204 mg/dL) and HDL-C
levelsinthelowertertile(≤0.88 mmol/Lor34 mg/dL)vs.simvastatin
monotherapy (Table 4).
107 The available data also suggest that fenoﬁ-
brateexertsmicrovascularbeneﬁts,notablyinpreventingprogression
of retinopathy in T2DM patients.
216,217
Concerns about the safety of statin–ﬁbrate combination therapy
relate chieﬂy to the risk of myopathy, although this is substantially
lower with fenoﬁbrate than gemﬁbrozil.
218 Current evidence based
on ACCORD Lipid suggests that the incidence of myopathy with
fenoﬁbrate–statin combination therapy is similar to that with
niacin–statin combination therapy.
107,219 There were no reports
of rhabdomyolysis with fenoﬁbrate–statin combination therapy
in either FIELD or ACCORD Lipid,
107,207 and in ACCORD Lipid
no increase in the incidence of venous thromboembolic disease,
pancreatitis, or non-CV mortality.
107 Fenoﬁbrate increased serum
creatinine and homocysteine (a rapidly reversible effect),
107,220
and in the FIELD Helsinki cohort, decreased creatinine clearance
and estimated glomerular ﬁltration rate, with no effect on the
urinary albumin creatinine ratio.
221 Elevated serum homocysteine
levels have been suggested as the basis for the neutral effect of
fenoﬁbrate on apo A-I.
222 The clinical signiﬁcance of these
effects remains unclear. Finally, all ﬁbrates are known to increase
the long-term risk of cholelithiasis.
218
In summary, statins ﬁrmly remain the ﬁrst line treatment of
choice for attainment of LDL-C goal in patients at high risk of
CVD.
4,5 After LDL-C goal attainment however, and if triglyceride
levels remain elevated (≥1.7 mmol/L or 150 mg/dL, as deﬁned
by recent European guidelines
4) and HDL-C low (,1.0 mmol/L
Figure 6 Proposed algorithm for the management of high-risk individuals with elevated triglycerides and/or low HDL cholesterol at LDL choles-
terol goal.
aLDL-C at goal as recommended by the most recent European guidelines (2007);
4 ,2.5 mmol/L in high-risk patients, decreasing to
,2.0 mmol/L in very high risk patients. High-dose omega-3 fatty acids, ﬁbrate, or niacin may be considered if the patient has very high TG
(.5.0 mmol/L)topreventpancreatitis.
bIfthepatientstillhaselevatedTG(≥1.7 mmol/L,asrecommendedbythemostrecentEuropeanguidelines
4)
and/orlowHDL-C(,1.0 mmol/L)despiteintensivelifestyleintervention,andaddressingcompliancewithpharmacotherapyandsecondarycausesof
dyslipidaemia,additionallipid-modifyingtherapymaybeconsidered.
cBasedonclinicaloutcomedataandsafetyconsiderationsforcombinationstatin–
ﬁbrate therapy, fenoﬁbrate is the preferred ﬁbrate. This ﬁbrate may have particular value in patients with T2DM and mild-to-moderate retinopathy.
dGreater LDL-C lowering may be achieved by the addition of ezetimibe to a statin. Ezetimibe has a dose-sparing advantage in patients intolerant of
higher dose statins, although outcome evidence to support its use is awaited. Note: To convert LDL-C or HDL-C from mmol/L to mg/dL multiply
by 38.7; to convert TG from mmol/L to mg/dL multiply by 88.5. Abbreviations: TG, triglycerides; HDL-C, high-density-lipoprotein cholesterol;
LDL-C, low-density-lipoprotein cholesterol.
TRL and HDL-C in patients at high risk of CVD 1357or 40 mg/dL) despite intensive lifestyle intervention, then addition
of a ﬁbrate or niacin may be considered (Figure 6).
Omega-3 fatty acids
Long chain omega-3 fatty acids [eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) 2–4 g/day] are approved as an
adjunct to diet for lowering plasma triglycerides when
.5.5 mmol/L (490 mg/dL) to prevent pancreatitis. The proﬁle of
lipid-modifying activity is given in Box 2 and mechanisms involved
are summarized in Table 3.
138,157,167–170
Outcome beneﬁts for omega-3 fatty acids have been reported
but relate to lower doses than required clinically to lower trigly-
cerides (Supplementary material online, Table S3).
223–225 These
beneﬁts may be explained by anti-arrhythmic effects, independent
of triglycerides.
226 The AFORRD trial in T2DM patients showed
no beneﬁt after 4 months of omega-3 fatty acids (2 g/day) in
combination with atorvastatin on estimated CV risk.
227 Adverse
effects are limited to minor dyspepsia, with no evidence of
increased risk of signiﬁcant bleeding, even with concomitant
aspirin or warfarin.
Future options
HDL-C-raising per se may represent a key determinant of
the clinical beneﬁts associated with lipid-modifying therapy,
228
although this concept still needs proof from randomized interven-
tion trials.
CETP inhibitors increase HDL-C levels substantially, and some
also affect LDL-C and triglyceride levels.
166 Dalcetrapib
(JTT-705) exerts moderate effects on plasma lipids (raising
HDL-C by up to 37%),
229 whereas torcetrapib was far more
potent (increases in HDL-C .70%), and modestly reduced
LDL-C ( 20%) and triglycerides (9%).
166 Despite this, the ﬁrst
outcome study with torcetrapib, ILLUMINATE, was prematurely
terminated due to excess mortality.
230 However, recent evi-
dence
231,232 suggests that off-target pharmacological effects of tor-
cetrapib were responsible for this adverse outcome rather than a
class effect of CETP inhibitors. In all trials, torcetrapib treatment
was associated with an increase in systolic blood pressure and elec-
trolyte changes, mediated via hyperaldosteronism. Concerns that
large HDL generated through CETP inhibition would be dysfunc-
tional have not been supported by in vitro studies.
233,234 Other
CETP inhibitors (e.g. dalcetrapib and anacetrapib) do not show
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Table 5 Evidence supporting the contention that elevated LDL-C, elevated fasting or non-fasting TRL and their
remnants, and subnormal HDL-C alone and/or together play causal roles in CVD
Type of evidence Elevated LDL-C Elevated TRL, their remnants or low HDL-C
Human epidemiology Direct association between
LDL-C and CVD in
numerous studies
Direct association between TG and CVD in numerous studies; association loston correction for
non-HDL-C and HDL-C in ERFC
93
Strong inverse association between low HDL-C and CVD in numerous studies; association
maintained after correction for TG and non-HDL-C in ERFC
93
Mechanistic studies Deﬁnitive mechanistic
evidence; LDL accumulate
in arterial intima and
promote atherosclerosis
Arterial accumulation of TRL and their remnants to promote atherosclerosis like LDL, with
potential pro-inﬂammatory and pro-thrombotic/anti-ﬁbrinolytic effects
In vitro and ex vivo evidence for potential anti-inﬂammatory vasculoprotective, anti-thrombotic
and cytoprotective effects of HDL particles; central implication of cholesterol acceptor
activity
Animal models Pro-atherogenic effect in
numerous studies
Pro-atherogenic and pro-inﬂammatory effects for TRL and their remnants
Atheroprotection exerted by elevated HDL or apo A-I levels
Human genetic
studies
Direct causal association in
numerous studies, and
notably in familial
hypercholesterolaemia
Dysbetalipoproteinaemia (remnant hyperlipidaemia , apo E2/E2) provides causal evidence for
the atherogenicity of elevated TRL and their remnants
Lack of deﬁnitive insight for HDL-C, potentially due to the complexity of HDL metabolism
Human intervention
studies
Statin trials provided
conclusive proof of
causality
Imaging trials reveal that ﬁbrate therapy may impact atherosclerosis progression but fails to slow
intima–media thickening; see Supplementary material online, Table S2
Meta-analysis of ﬁbrate trials (+statin) show clinical beneﬁt limited to non-fatal CV events.
208
Subgroup analyses reveal major reduction in CV events in patients with high TG and low
HDL-C
211
Niacin imaging trials showed consistent stabilization and/or regression of atherosclerosis or
intima–media thickening in monotherapy or in combination; see Supplementary material
online, Table S1
Reduction in CV events and total mortality with niacin monotherapy
183,184
Interpretation 2010
a Deﬁnite causality Evidence suggestive of a strong causal association of atherogenic dyslipidaemia, i.e. elevated TRL
and their remnants combined with low HDL-C
Insufﬁcient evidence for TRL and their remnants alone
Insufﬁcient evidence for low HDL-C alone
aForan interpretationof causality given the dataavailable in 2010, all ﬁvetypes of evidence should favourcausality and all three types of human studies (epidemiology, genetics, and
intervention trials) must be consistent; this is clearly the case for elevated LDL-C.
M.J. Chapman et al. 1358the off-target effects associated with torcetrapib, as indicated by
recent studies.
235,236 Clinical outcome data from ongoing or
planned studies (dal-OUTCOMES with dalcetrapib and REVEAL
with anacetrapib) are awaited.
What is the evidence for a causal
role of elevated triglyceride-rich
lipoprotein and their remnants
and/or low high-density lipoprotein
cholesterol in premature
atherosclerosis and cardiovascular
disease?
The EAS Consensus Panel considers that for an interpretation of
causality, ﬁve types of evidence should each favour causality
(Table 5) with consistent evidence required from all three types
of clinical evidence (epidemiology, genetics, and intervention
trials).
237 For elevated LDL-C, the consensus is deﬁnite causality.
The Panel contends, on the basis of available evidence, that elev-
ated TRL and their remnants combined with low HDL-C may
also play a causal role in premature atherosclerosis, whereas insuf-
ﬁcient data are currently available for assessing the causality of TRL
and remnants alone. The clinical relevance of isolated low HDL-C
to CVD also remains unclear.
238
Guidance for clinical management
The EAS Consensus Panel believes that targeting a high triglyceride/
lowHDL-CphenotypeislikelytobebeneﬁcialinpatientswithCVD
or at high risk of CVD, especially those with cardiometabolic
abnormalities. The therapeutic needs of these patients are likely to
exceed LDL-C lowering by statin monotherapy.
239 The rec-
ommended steps for managing these patients after achieving
LDL-C goal, as deﬁned by the most recent European guidelines,
4
are summarized in Figure 6. The Panel proposes triglycerides as a
marker for TRL and their remnants. Elevated triglycerides
(≥1.7 mmol/L or 150 mg/dL, consistent with European guidelines
4)
and/orlowHDL-C(,1.0 mmol/Lor40 mg/dL)aretriggersforcon-
sidering further treatment in both men and women. HDL-C levels
,1.0 mmol/L (40 mg/dL) in men and ,1.2 mmol/L (45 mg/dL) in
women are also considered a CV risk factor in current European
guidelines.
4 It is noteworthy that in ACCORD Lipid, a cutoff for tri-
glycerides of ≥2.3 mmol/L identiﬁed statin-treated patients at high
CV risk, who may respond to ﬁbrates.
107 For simplicity and conven-
ience, measurement of non-fasting plasma lipids is recommended,
supported by data from the ERFC,
93 but care should be taken
wheninterpretingtriglyceridelevelsinindividualswhohaverecently
consumed a high-fat meal.
The Panel stresses that lifestyle modiﬁcations (Box 5) should
underpin the management of all patients at increased CV risk,
especially those with elevated triglycerides (≥1.7 mmol/L or
150 mg/dL) and/or low plasma levels of HDL-C (,1.0 mmol/L or
40 mg/dL). As non-compliance can be a signiﬁcant issue, addressing
its causes and identifying solutions, including improvement in
physician–patient alliance is essential. Secondary causes of dyslipi-
daemia, including poor glycaemic control, obesity, diets high in
reﬁned carbohydrates, alcohol excess, lack of exercise, and
smokingmustbeaddressed.Despiteadherencetolifestyleinterven-
tions, it is likely that many of these patients with atherogenic dyslipi-
daemia will require pharmacotherapy. At least 50% of all high-risk
patients on a statin may require optimization of treatment to
further lower LDL-C,
240 and about 10–15%
107 may need additional
treatment for elevated triglycerides and/or low HDL-C. In
these patients, clinicians may consider adding niacin or a ﬁbrate,
while taking into account potential safety issues, as discussed in
this paper.
Box 5 Recommended basic lifestyle
interventions to lower triglycerides and
increase HDL-C
† Stop smoking: all smokers at high cardiovascular risk unable
to quit smoking should be referred to specialized smoking
cessation clinics
† Increase physical activity: aim for at least 30 min of moder-
ate aerobic activity (activity producing a heart rate of
60–75% of age-related maximum heart rate) for at least
5 days per week
† Adopt a Mediterranean-type diet characterized by high
monounsaturated and low saturated fatty acids, and low-
carbohydrate content. Avoid reﬁned sugar and fructose rich
diets which aggravate dyslipidaemia. Increase intake of
complex carbohydrates, viscous ﬁbre, and whole-grains
† Lose weight: obese and overweight subjects should adopt a
calorie restriction diet, aiming to achieve optimal weight or
at least to lose 10% of body weight
† Restrict alcohol intake to less than 30 g per day (,20 g/day
in women). Avoid alcohol consumption in case of high
triglyceride levels
In view of its broad spectrum lipid-modulating actions in atherogenic
dyslipidaemia (Box 2), niacin may be of special value for reducing TRL
and their remnants concomitant with raising HDL-C levels among
patients with cardiometabolic abnormalities, particularly those with
insulin resistance. However, deﬁnitive data from AIM-HIGH and
HPS2-THRIVE are needed. Niacin is also unique in lowering Lp(a)
levels.
35 Treatment with niacin is supported by clinical evidence of
stabilization or regression of atherosclerosis in clinical trials (see
Niacin subsection). In practice, plasma glucose and urate levels should
be monitored regularly for the possibility of hyperglycaemia and
hyperuricaemia, respectively, and liver function tests should be mon-
itored to exclude hepatotoxicity. In patients with impaired fasting
glucose or impaired glucose tolerance, lifestyle modiﬁcation is the
ﬁrst option to control glucose, and if niacin is introduced glucose
levels should be monitored.
The current level of evidence for clinical outcomes beneﬁts and
safety suggests that fenoﬁbrate may be the preferred ﬁbrate for
combination with a statin, and may also have particular value in
T2DM patients with mild-to-moderate retinopathy.
216,217 From a
safety perspective, pre-treatment serum transaminases, creatine
TRL and HDL-C in patients at high risk of CVD 1359(phospho)kinase, and creatinine should be measured. Creatine
(phospho)kinase should be repeated if myalgia is reported, or
there are known risk factors for myopathy, and treatment discon-
tinued if levels exceed ﬁve times the upper limit of normal and/or
symptoms are severe. Alanine and aspartate transaminases should
be monitored 3 months after starting therapy and annually there-
after, but more frequently if the dose of statin is uptitrated.
Serum creatinine should be monitored with statin–fenoﬁbrate
combinations.
If patients are intolerant of both niacin and fenoﬁbrate, a high
dose of omega-3 fatty acids ethyl esters may be considered. In
patients with very high triglycerides (.5.5 mmol/L or 490 mg/
dL), fenoﬁbrate, niacin, or high-dose omega-3 fatty acids (3–4 g/
day), together with a very low fat diet (,10% of calorie intake)
and reduced alcohol intake, are recommended to prevent acute
pancreatitis consistent with current guidelines.
4
The Panel believes there is insufﬁcient evidence to permit deﬁ-
nition of targets for triglycerides or HDL-C for these high-risk
patients. Instead, the Panel proposes that treatment should be tai-
lored to the individual to achieve desirable levels below (for trigly-
cerides or non-HDL-C) or above (for HDL-C) the recommended
cut-offs (Box 6). The Panel acknowledges that other expert bodies
recommend apo B as a secondary therapeutic target in hypertrigly-
ceridaemic patients,
18.19 but considers that the precise clinical yield
of this approach has yet to be demonstrated. The Panel also recog-
nizes the limitations of the current evidence base for ﬁbrates,
niacin, and omega-3 fatty acids, including the lack of hard
outcome data for statin–niacin and statin–omega-3 fatty acid com-
bination therapies. Clearly, there is a need for well-deﬁned trials to
evaluate the efﬁcacy and safety of these therapeutic combinations
in high-risk patients at LDL-C goal with elevated triglycerides and/
or low HDL-C.
Box 6 Desirable lipid levels in patients
at high risk of CVD, according to recent
European guidelines
4
LDL-C ,2.5 mmol/L (100 mg/dL) in high risk;
,2.0 mmol/L (80 mg/dL) in very high risk
Triglycerides ,1.7 mmol/L (150 mg/dL)
HDL-C .1.0 mmol/L (40 mg/dL) in men;
.1.2 mmol/l (45 mg/dL) in women
Non-HDL-C ,2.5 mmol/L (100 mg/dL)
Conclusions
The EAS Consensus Panel believes that adoption of these
recommendations for clinical management of elevated triglycer-
ides, a marker of TRL and their remnants, and/or low concen-
trations of HDL-C, supported by appraisal of the current
evidence, will facilitate reduction in the substantial CV risk that
persists in high-risk patients at LDL-C goal, especially those with
cardiometabolic abnormalities (Box 7).
Box 7 Key messages
† High-risk individuals, especially with cardiometabolic
disease, who achieve LDL-C goals remain at high risk of
CV events
† Appraisal of the current evidence base implicates elevated
triglycerides, a marker of TRL and their remnants, and low
levels of HDL-C in this excess CV risk
† In clinical intervention studies using surrogate outcome
measures, the addition of niacin to statin reduced athero-
sclerosis progression in high-risk patients with low
LDL-C and elevated triglycerides and/or low HDL-C. Sub-
group analyses also showed additional reduction in CV
events with ﬁbrate therapy, either alone or in combination
with a statin, in patients with atherogenic dyslipidaemia
† Consistent with European guidelines,
4 elevated triglycer-
ides (≥1.7 mmol/L or 150 mg/dL) and/or low HDL-C
levels (,1.0 mmol/L or 40 mg/dL) should be triggers for
considering further treatment in high-risk individuals
† Lifestyle intervention and addressing compliance and sec-
ondary causes of dyslipidaemia constitutes the ﬁrst step
in management
† Adding niacin or a ﬁbrate, or intensifying LDL-C lowering,
are suggested options for correction of atherogenic
dyslipidaemia
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